Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02113631 · ClinicalTrials.gov registry record · NA

Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir

A NA study, sponsored by Louis Stokes VA Medical Center.

Completed
Registry status
NA
Development phase
50
Enrollment target

NCT02113631: Completed NA study, sponsored by Louis Stokes VA Medical Center.

NCT02113631 is a NA study that has completed, run by Louis Stokes VA Medical Center. The registered enrollment target is 50 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02113631, a NA study, has completed, sponsored by Louis Stokes VA Medical Center.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target

Study Summary

1. The primary objective is to study the comparative effectiveness and tolerability of boceprevir vs. telaprevir in HCV treatment, within the VA population. 2. The secondary objective: * Resource use: recording of differences in resource use, such as direct costs (e.g., drug acquisition costs) and other indirect cost (e.g., staff utilization etc.) as the study will not only derive data by comparing those two drugs but also study the effect on different treatment lengths.

Primary Outcome

Number of Participants with Serious and Non-Serious Adverse Events

Interventions

  • DRUG Peg-IFN
  • DRUG Ribavirin
  • DRUG Telaprevir
  • DRUG Boceprevir

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2011-09
Est. Completion 2013-04
Phase NA
Louis Stokes VA Medical Center

10 total trials

What the finished NCT02113631 record still lists

NCT02113631 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 4 interventions - of which Peg-IFN is the first listed.

NCT02113631 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02113631 about?

NCT02113631 is a clinical study titled "Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir". 1. The primary objective is to study the comparative effectiveness and tolerability of boceprevir vs. telaprevir in HCV treatment, within the VA population. 2. The secondary objective: * Resource use: recording of differences in resource use, such as direct costs (e.g., drug acquisition costs) a...

What is the current status of trial NCT02113631?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2011-09. Estimated completion is 2013-04.

What interventions are being tested in trial NCT02113631?

The interventions under investigation include: Peg-IFN (DRUG), Ribavirin (DRUG), Telaprevir (DRUG), Boceprevir (DRUG).

Who is sponsoring clinical trial NCT02113631?

This trial is sponsored by Louis Stokes VA Medical Center, which has 10 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02113631's enrollment target sits among peer trials

50 1279th of 2000 higher than 622 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02113631, the US trial registry maintained by the National Library of Medicine. NCT02113631 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.